Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.
Type:
Grant
Filed:
March 17, 2003
Date of Patent:
April 10, 2007
Assignee:
Hemavation, LLC
Inventors:
Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
Abstract: A medical needle for withdrawal of blood from a patient or for insertion in medicinal containers in which the end of a needle extending from the body of a syringe is provided with one or more marks at its end region to indicate the depth of penetration of the needle below the skin surface of a patient in a given site so that the depth of penetration can be indicated as well as the degree of withdrawal of the needle in such instances as when the needle is required to be partially pulled out maneuvered below the skin to seek an artery for withdrawal of blood. In addition, the end of the needle is provided with coloring and a marking such that it is more visible than the bare stainless steel needles of conventional type thereby assisting in prevention of accidental needle sticks in either the technician or the patient.
Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF.